Stephane Bancel
CIK 1443340 · Chief Executive Officer · last filed 2026-03-03
Stephane Bancel is a Chief Executive Officer who has filed 322 SEC Form 4 insider transactions across 5 companies since 2008. The most recent filing, for MRNA, was dated Mar 3, 2026. Across all open-market trades the lifetime net is −$1.19B, making them a net seller over the disclosed history. Current disclosed insider exposure totals $871.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$871.05M
5
322
-$1.19B
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MRNA | Chief Executive Officer | 15,398,477 | $55.57 | $855.69M | -$1.19B | 284 | 2026-03-03 |
| GENB | Director | 1,184,989 | $12.96 | $15.36M | $0 | 1 | 2026-03-02 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | Director | 4,798 | $0.00 | $2 | $0 | 2 | 2016-09-19 |
| BG Medicine, Inc. (BGMD) Delisted | Executive Chairman | 30,792 | — | — | $226.1K | 11 | 2013-11-04 |
| Targanta Therapeutics Corp. (TARG) Delisted | Director | — | — | — | $0 | 1 | 2008-08-26 |
Recent Filings
322 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-03 | MRNA | Grant (A) | — | $0 | EDGAR |
| 2026-03-02 | GENB | Mixed | +724,160 | $0 | EDGAR |
| 2026-02-13 | MRNA | Mixed | +5,821 | -$228.8K | EDGAR |
| 2025-12-15 | MRNA | Exer (M) | +688,073 | $7.50M | EDGAR |
| 2025-03-04 | MRNA | Buy (P) | +160,314 | $5.00M | EDGAR |
| 2025-03-03 | MRNA | Grant (A) | — | $0 | EDGAR |
| 2025-02-14 | MRNA | Mixed | +6,833 | -$198.0K | EDGAR |
| 2024-06-17 | MRNA | Other (J) | +26,840 | $0 | EDGAR |
| 2024-02-29 | MRNA | Grant (A) | — | $0 | EDGAR |
| 2024-02-16 | MRNA | Notice (144) | −26,351 | -$2.34M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.